Press release
Top Trends Transforming the Roxadustat Market Landscape in 2025: Roxadustat Reimbursement Under Ireland's High Tech Drugs Scheme Accelerates Market Growth
Roxadustat
What Will the Roxadustat Industry Market Size Be by 2025?
There has been a robust growth in the roxadustat market in the past few years. The market is predicted to expand from a size of $6.44 billion in 2024 to $6.86 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The factors contributing to this consistent growth during the historical phase include regulatory authorizations in key markets, compelling results from clinical trials, the growing incidence of chronic kidney disease, heightened awareness about anemia management, and governmental backing for anemia therapies.
What's the Long-Term Growth Forecast for the Roxadustat Market Size Through 2029?
In the coming years, the roxadustat market is projected to experience robust growth, reaching a value of $8.95 billion by 2029, increasing at a compound annual growth rate (CAGR) of 6.9%. This growth over the forecast period may be driven by the ongoing investigations for new applications, growing healthcare spending, the rising demand for non-invasive anemia treatments, broadening insurance coverages, and an increasing aging population. Key trends for the forecast period include a move towards oral anemia remedies, intensifying competition from alternative treatment methods, the expansion of licensing deals, increasing investments in hypoxia-inducible factor research, and an emphasis on patient-centric treatment methods.
View the full report here:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report
What Are the Key Growth Drivers Fueling the Roxadustat Market Expansion?
The escalating prevalence of individuals suffering from chronic kidney disease (CKD) is anticipated to stimulate the expansion of the Roxadustat market in the future. Chronic kidney disease, a protracted condition characterized by a steady decrease in kidney functionality, poses the threat of kidney failure if not appropriately addressed. The global increase in CKD cases can be attributed to factors like ageing demographic, growing rate of diabetes, hypertension and unhealthy living habits. Roxadustat assists in the regulation of CKD by promoting the production of erythropoietin, thereby enhancing red blood cell production and alleviating anemia often connected with this ailment which ultimately betters kidney function and living standards for those affected. For example, a study by the Australian Institute of Health and Welfare (AIHW), a government institution in Australia, showed a slight annual surge in the mortality rates from chronic kidney disease, recording increases of 4.2% in 2021 and 6.2% in 2022. Consequently, this rising prevalence of people suffering from chronic kidney disease (CKD) is intensifying the expansion of the Roxadustat market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Roxadustat Market?
Prominent corporations engaged in the Roxadustat market are pursuing reimbursement under the high-tech drugs scheme. This strategy aims to remove financial hurdles to patient accessibility, propel market uptake, and exhibit the cost-effectiveness of their groundbreaking treatments. The high-tech drugs program is predominantly overseen by the Irish government and reimburses the provision of costly, highly bespoke medications usually prescribed in hospital contexts. For example, in September 2022, Astellas Pharma Company Ltd., a US-located pharmaceutical firm disclosed that its product, EVRENZO (Roxadustat), has been approved for reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the inaugural drug from the novel class of oral hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitors licensed and reimbursed in Ireland. The outcome illustrated that Roxadustat was successful in attaining and retaining target hemoglobin rates (10-12g/dL) in patients suffering from symptomatic anemia of CKD, no matter their dialysis status and previous ESA treatment.
How Is the Roxadustat Market Segmented?
The roxadustat market covered in this report is segmented -
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp
Which Companies Are Leading the Charge in Roxadustat Market Innovation?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
Which Regions Are Leading the Global Roxadustat Market in Revenue?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Trends Transforming the Roxadustat Market Landscape in 2025: Roxadustat Reimbursement Under Ireland's High Tech Drugs Scheme Accelerates Market Growth here
News-ID: 4184029 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Roxadustat
Roxadustat Market Size Projected To Reach 9.15 Billion By 2034 With A Cagr Of 7. …
"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Projected Growth of the Roxadustat Market?
Over the past few years, the Roxadustat market has exhibited robust growth. It is projected to rise from $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as regulatory green signals in…
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
Roxadustat Market Industry Analysis by Size, Share, Growth, Sourcing Strategy, S …
" As of 2024, the global Roxadustat market is valued at approximately $1.1 billion, driven by increasing demand for innovative therapies to treat anemia, particularly in patients with chronic kidney disease (CKD). The market is projected to grow to around $3.2 billion by 2034, reflecting a robust expansion fueled by an aging population, escalating CKD prevalence, and ongoing clinical research into Roxadustat's efficacy."
Exactitude Consultancy., Ltd. released a research report titled…
In-Depth Analysis of the Roxadustat Market: Growth Opportunities, Key Trends, an …
What industry-specific factors are fueling the growth of the roxadustat market?
The growing number of individuals with chronic kidney disease (CKD) is expected to drive the growth of the Roxadustat market. CKD is a long-term condition in which the kidneys progressively lose their ability to function properly, potentially leading to kidney failure if untreated. The rising number of CKD patients globally is attributed to factors such as aging populations, increased rates…
Chemotherapy Induced Anemia Market Forecast 2032: FDA, EMA, PDMA Approvals, Clin …
Chemotherapy Induced Anemia companies are Astellas, FibroGen, AstraZeneca, Aileron Therapeutics, Zydus Cadila, Pfizer Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb, FibroGen, and others.
(Albany, USA) DelveInsight's "Chemotherapy Induced Anemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Chemotherapy Induced Anemia, historical and forecasted epidemiology as well as the Chemotherapy Induced Anemia market trends in the United States, EU5…
Chemotherapy Induced Anemia Pipeline Analysis (2023) Covering Clinical Trials, E …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, several major pharma and biotech companies are actively developing novel therapies in the Chemotherapy Induced Anemia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Chemotherapy Induced Anemia Pipeline Insight, 2023" report…
